Compare Boston Scientific Corporation (BSX) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs ABRDN Physical Gold Shares ETF — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while ABRDN Physical Gold Shares ETF trades at $38.65. The key difference: ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | SGOL | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $108.14 | $51.41 |
52-Week Low | $42.63 | $31.18 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
SGOL is trading at $38.1, down 2.61% amid broader gold market weakness. The technical picture shows bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. Gold ETFs face headwinds from rising Treasury yields and Federal Reserve policy uncertainty, though central bank buying provides underlying support. Recent CPI data provided temporary relief but failed to sustain momentum.
The outlook remains cautious as gold faces competing forces - supportive central bank demand versus restrictive monetary policy. Near-term direction hinges on Fed policy clarity and inflation trends, with technical resistance at $39-$40 levels posing immediate challenges for bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
